Overview

The purpose of the study is to develop an acceptable, feasible, and effective peer-led bundle of harm reduction services to be delivered in the hospital setting, called the THRIVE intervention.

The main question it aims to answer is: Will participants receiving the THRIVE intervention have a reduced risk of self-reported non-fatal overdoses OR skin/soft tissue infections compared to participants receiving enhanced usual care?

Researchers will compare the THRIVE model to enhanced usual care to see if the THRIVE model helps participants reduce their number of self-reported non-fatal overdoses OR skin/soft tissue infections.

Intervention participants will:

• Receive one in-person session from a peer support specialist while in the hospital
• Receive weekly text messages from the peer support specialist for a 12-week period
• Receive monthly, multiple-choice assessments via text message at Month 1, 2, 3, 4, 5, and 6
• Complete a baseline, 3-month, and 6-month assessment with Research Assistants

Enhanced usual care participants will:

• Receive a handout with harm reduction education and resources in their local area
• Receive monthly, multiple-choice assessments via text message at Month 1, 2, 3, 4, 5, and 6
• Complete a baseline, 3-month, and 6-month assessment with Research Assistants

Eligibility

Inclusion Criteria:

• Participants who are: a) admitted to University of Pittsburgh Medical Center (UPMC) Shadyside Hospital, UPMC Presbyterian-Montefiore Hospital, UPMC Mercy Hospital for inpatient or observation status, or b) seen in the Emergency Department setting at UPMC Presbyterian-Montefiore Hospital and UPMC Mercy Hospital.
• Participants must have a current diagnosis of Opioid Use Disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria.
• Participants must be at least 18 years of age on day of admission.
• Participants must be able to speak and read English.

Exclusion Criteria:

• Participants diagnosed with dementia and/or cognitive impairments.
• Participants with acute psychiatric complications, such as schizophrenia with acute psychosis, acute mania, or suicidal ideation (which may impact the ability of a participant to consent and actively participate in treatment).
• Participants who are pregnant or lactating at onset of study.
• Participants who cannot read or speak English.